tetano
Editor, Senior Moderator
Sci Adv
. 2023 Sep 22;9(38):eadh1655.
doi: 10.1126/sciadv.adh1655. Epub 2023 Sep 22. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Gabriela Baldeon Vaca[SUP] 1 [/SUP], Michelle Meyer[SUP] 2 3 [/SUP], Ana Cadete[SUP] 1 [/SUP], Chiaowen Joyce Hsiao[SUP] 1 [/SUP], Anne Golding[SUP] 1 [/SUP], Albert Jeon[SUP] 1 [/SUP], Eric Jacquinet[SUP] 1 [/SUP], Emily Azcue[SUP] 1 [/SUP], Chenxia Monica Guan[SUP] 1 [/SUP], Xavier Sanchez-Felix[SUP] 1 [/SUP], Colette A Pietzsch[SUP] 2 3 [/SUP], Chad E Mire[SUP] 2 3 [/SUP], Matthew A Hyde[SUP] 2 3 [/SUP], Margaret E Comeaux[SUP] 2 3 [/SUP], Julie M Williams[SUP] 2 3 [/SUP], Jean C Sung[SUP] 1 [/SUP], Andrea Carfi[SUP] 1 [/SUP], Darin K Edwards[SUP] 1 [/SUP], Alexander Bukreyev[SUP] 2 3 4 [/SUP], Kapil Bahl[SUP] 1 [/SUP]
Affiliations
Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.
. 2023 Sep 22;9(38):eadh1655.
doi: 10.1126/sciadv.adh1655. Epub 2023 Sep 22. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Gabriela Baldeon Vaca[SUP] 1 [/SUP], Michelle Meyer[SUP] 2 3 [/SUP], Ana Cadete[SUP] 1 [/SUP], Chiaowen Joyce Hsiao[SUP] 1 [/SUP], Anne Golding[SUP] 1 [/SUP], Albert Jeon[SUP] 1 [/SUP], Eric Jacquinet[SUP] 1 [/SUP], Emily Azcue[SUP] 1 [/SUP], Chenxia Monica Guan[SUP] 1 [/SUP], Xavier Sanchez-Felix[SUP] 1 [/SUP], Colette A Pietzsch[SUP] 2 3 [/SUP], Chad E Mire[SUP] 2 3 [/SUP], Matthew A Hyde[SUP] 2 3 [/SUP], Margaret E Comeaux[SUP] 2 3 [/SUP], Julie M Williams[SUP] 2 3 [/SUP], Jean C Sung[SUP] 1 [/SUP], Andrea Carfi[SUP] 1 [/SUP], Darin K Edwards[SUP] 1 [/SUP], Alexander Bukreyev[SUP] 2 3 4 [/SUP], Kapil Bahl[SUP] 1 [/SUP]
Affiliations
- PMID: 37738334
- DOI: 10.1126/sciadv.adh1655
Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.